Bevacizumab and quality of life in advanced cervical cancer

David Cella

doi:10.1016/S1470-2045(15)70052-5

Bevacizumab and quality of life in advanced cervical cancer

David Cella^*

^*Corresponding author for this work

Medical Social Sciences

Research output: Contribution to journal › Comment/debate › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	241-243
Number of pages	3
Journal	The Lancet Oncology
Volume	16
Issue number	3
DOIs	https://doi.org/10.1016/S1470-2045(15)70052-5
State	Published - Mar 1 2015

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(15)70052-5

Cite this

@article{48dab021078e4e0bb9ac2ac84021de09,

title = "Bevacizumab and quality of life in advanced cervical cancer",

author = "David Cella",

year = "2015",

month = mar,

day = "1",

doi = "10.1016/S1470-2045(15)70052-5",

language = "English (US)",

volume = "16",

pages = "241--243",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "3",

}

TY - JOUR

T1 - Bevacizumab and quality of life in advanced cervical cancer

AU - Cella, David

PY - 2015/3/1

Y1 - 2015/3/1

UR - http://www.scopus.com/inward/record.url?scp=84924902642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924902642&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(15)70052-5

DO - 10.1016/S1470-2045(15)70052-5

M3 - Comment/debate

C2 - 25752545

AN - SCOPUS:84924902642

SN - 1470-2045

VL - 16

SP - 241

EP - 243

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 3

ER -

Bevacizumab and quality of life in advanced cervical cancer

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this